“Lenvatinib Is More Effective & Safer Than Sorafenib in the Treatment of Renal Cell Carcinoma - A Single-Center Retrospective Analysis of 70 Cases”. Journal of Carcinogenesis 23, no. 1 (December 18, 2024): 624–628. Accessed January 16, 2026. https://carcinogenesis.com/index.php/JOC/article/view/1770.